This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 07 August 2024; doi:10.1038/s41569-024-01064-4 In this Review, Ghofrani and colleagues discuss the mechanisms underlying the development of pulmonary arterial hypertension, provide an overview of approved therapies and describe the predominantly non-vasodilatory drugs that are currently being tested in clinical (..)
(Credit: Feinstein Institutes) milla1cf Wed, 05/08/2024 - 10:57 May 8, 2024 — Ultrasound could one day complement or even replace drugs to treat diseases. PAH is caused by constriction and wall thickening of pulmonary arteries that carry blood from the heart to the lungs for oxygenation.
The use of hormone replacement therapy (HRT) may be associated with improved pulmonary hypertension in women, according to research presented at the ATS 2024 International Conference held May 17–22 in San Diego.
milla1cf Tue, 02/27/2024 - 17:29 February 27, 2024 — Aria CV, Inc , a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St.
Getty Images mtaschetta-millane Wed, 07/10/2024 - 08:51 July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc. , Founder, President, and CEO. Brilaroxazine has demonstrated a favorable clinical safety and tolerability profile in over 800 subjects to date from multiple clinical trials.
milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024.
They looked at anonymous results for 57,531 adult patients who underwent pulmonary resection—removal of all or part of a lung—between January 2009 and June 2021. occurrence of postoperative PE in patients undergoing a first-time pulmonary resection for lung cancer. occurrence of postoperative VTE and a 1.3%
During the surgery, the malfunctioning aortic valve is replaced with the patients own healthy pulmonary valvea technique called an autograftand the pulmonary valve replaced with donor tissue. Three patients underwent the Ross-Konno procedure, in which the left-sided outflow root is enlarged to fit the pulmonary autograft.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
The independent risk factors for mortality included left ventricular ejection fraction (LVEF), pulmonary hypertension, and low-density lipoprotein (LDL) levels (P<0.05). LVEF, pulmonary hypertension, and LDL levels are critical prognostic factors, offering insights for risk assessment and management in affected children.
In addition, the advent of new care models, including virtual and remote delivery of cardiac rehabilitation services, has expanded the ways that cardiac rehabilitation programs can reach patients.
This review of May 2024 covered several notable topics in the pulmonary health field, including research into vaping, lung abnormalities, and treatment of COPD.
In this review of April 2024, the editorial team highlighted some of the biggest stories in the pulmonary health space, touching on topics such as air quality issues, asthma, and pneumonia.
He was started on a heparin drip and CTA of the chest was ordered to rule out pulmonary embolism. This is a case like many others posted (see list below) and the EKG from the patient’s original presentation can be quickly recognized as diagnostic for pulmonary embolism. Accessed May 28, 2024. In fact, Kosuge et al.
Circulation, Volume 150, Issue Suppl_1 , Page A4120743-A4120743, November 12, 2024. However, the most recurrent cardiac complication in RASopathies is pulmonary valve stenosis (PVS). Backgound:The RASopathies are developmental syndromes resulting from variants in the RAS/mitogen-activated protein (MAPK) cascade.
Resource Pulmonary Resection for Lung Cancer Risk Calculator gmckinney Wed, 10/16/2024 - 07:59 The new pulmonary resection for lung cancer risk calculator is engineered using contemporary data from the STS General Thoracic Surgery Database.
The first half of 2024 has ushered in a wave of transformative FDA approvals in cardiorenal metabolic health. Edwards EVOQUE Tricuspid Valve Replacement System (Approved: 02/01/2024) This system provides a novel approach to tricuspid valve replacement, potentially benefiting patients with tricuspid regurgitation without open-heart surgery.
BackgroundPercutaneous mechanical thrombectomy (PMT) is increasingly used in the treatment of intermediate and high-risk acute pulmonary embolism (PE), and the treatment of high-risk PE with the aid of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has also been reported. The mortality rate was 27.3% during the 90-day follow-up.
tim.hodson Wed, 09/04/2024 - 15:34 Aug. 29, 2024 – Jupiter Endovascular, Inc., SPIRARE II is a prospective, single-arm, multicenter pivotal trial that will enroll up to 145 patients with acute, intermediate-risk PE treated with the Vertex Pulmonary Embolectomy System at up to 25 U.S. recently announced that the U.S.
This Month in Review summarizes some of the most significant stories covered in the month of August in the pulmonary health space, including new research and FDA news.
The European Society of Cardiology (ESC) Congress 2024 (August 30 – September 2, 2024) has wrapped up, delivering groundbreaking insights into cardiovascular diseases and related conditions. Suggest using MRAs before beta-blockers in cases of resistant hypertension. Explore 2024 ESC Updated Guidelines here.
== Review of ECG Rhythms — MIS-C Case Report ( 9/5 /2024 ): == What follows below are my first impressions of the ECG rhythms sent to me from the Case Report by Dimah Jarmakani et al — of a 12-year old boy with MIS-C ( M ultisystem I nflammatory S yndrome in C hildren ). RED arrows show what looks to be sinus P waves that are HUGE !!!!
A new Intelligent thrombo-suction catheter system , is being introduced for treatment of acute pulmonary embolism.This device regulates the force with which thrombus is sucked , with less injury and bleeding and better outcomes. Human studies & Evidence The experience from this device was presented in ESC 2024 London.
Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. The Ablamap System includes a workstation with software and monitor, amplifier, and proprietary basket mapping catheter and cables. "I
Pulmonary hypertension is a rare disease, associated with a significant deterioration in quality of life, usually not curable and with an ominous prognosis. We present the case of a patient diagnosed with precapillary component pulmonary hypertension, with the finding of an arteriovenous fistula at the peripheral level.
Event 2024 STS Coding Workshop dkaczmarek Thu, 11/16/2023 - 11:37 Event dates Feb 23–24, 2024 Register Now Location Virtual Register Now Add to calendar. Upon completion of this activity, participants should be able to: Identify new CPT codes, updates, and payment policies affecting cardiothoracic surgery coding for 2024.
milla1cf Wed, 05/22/2024 - 07:00 May 22, 2024 — Voiant (USA) and Thirona (The Netherlands) announced they have entered a global commercial partnership, combining Voiant's expertise in supporting clinical trials in pulmonary drug and treatment development with Thirona's expertise in advanced lung image analysis.
milla1cf Tue, 03/26/2024 - 11:12 March 26, 2024 — Medical imaging AI company Avicenna.AI announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI
4, 2025 Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 new customers with its ClearRead solutions to clearly, confidently and quickly detect cardiothoracic diseases. Our 2024 growth was driven by strong product market acceptance through network effects. MD, Thrap, K.,
mtaschetta-millane Wed, 07/31/2024 - 07:00 July 31, 2024 — BioCardia, Inc. , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, reported it has submitted a 510(k) for approval of its patented Morph DNA Steerable Introducer Sheath.
Circulation, Volume 150, Issue Suppl_1 , Page A4146398-A4146398, November 12, 2024. Rationale:Pulmonary arterial hypertension (PAH) is a devastating disease characterized by a progressive rise in pulmonary vascular resistance and occlusive vascular remodeling, leading to right heart failure and premature death.
In patients with narrow QRS ( not this patient), this pattern is highly suggestive of acute pulmonary embolism. Although it was technically difficult and the quality therefore leaves a lot to be desired, you can still make out RV dilation and septal flattening which is much more suggestive of pulmonary embolism than OMI.
Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10.
A company statement reported that its PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., Image courtesy: Boston Scientific christine.book Wed, 01/31/2024 - 11:13 January 31, 2024 — Boston Scientific Corporation announced it has received U.S.
Circulation, Volume 150, Issue Suppl_1 , Page A4143390-A4143390, November 12, 2024. Introduction:Obesity is rising in prevalence worldwide and co-exists in patients with group 1 pulmonary hypertension (PH). Despite having group 1 PH, pulmonary capillary wedge pressure (PCWP) was higher with obesity (13.8 ± 6.3 vs 10.4 ± 6.5
Nature Reviews Cardiology, Published online: 22 February 2024; doi:10.1038/s41569-024-01002-4 Using a porcine model of cardiogenic shock, Lamberti and colleagues develop a clinically accessible, patient-validated metric to assess pulmonary vascular compliance that can predict tolerance to left-sided ventricular assist device support.
Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.
Late-breaking data from the ENGULF trial showed that a novel dual-action thrombectomy device was effective and safe in treating acute pulmonary embolism (PE).
Circulation, Volume 150, Issue Suppl_1 , Page A4142839-A4142839, November 12, 2024. Introduction:Inflammation is a key driver in the development of pulmonary arterial hypertension (PAH). The pulmonary vasculature was evaluated histologically. The gut microbiome is a complex ecosystem consisting of trillions of organisms, 0.1%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content